header logo image


Page 39«..1020..38394041..»

Archive for December, 2020

Allergy experts weigh in on prevention strategies – Contemporary Pediatrics

Friday, December 4th, 2020

The American Academy of Allergy, Asthma, and Immunology (AAAAI) has unveiled new guidelines on preventing allergies and asthma in children.1 The guidance, updated in September, reviews a number of strategies to prevent, or even delay, the development of several types of allergies.

Food Allergies

Food allergies are a big deal in children, who arent always able to be choosy when it comes to what they eat. Children can have a difficult time discerning the content of some foods, and parents cant always be with them. This makes prevention key when it comes to food allergies, which can be triggered by a number of foods like peanuts, cows milk, eggs, and more.

Infants who have a sibling or at least 1 parent with an allergic condition are particularly at risk of developing food allergies, especially if they already show symptoms of foods allergies like atopic dermatitis, allergic rhinitis, or asthma.

There are a number of methods that helpand others that dontthat were reviewed in the guidance.

Environmental Allergies

There are a number of environmental factors that can trigger allergies, too. However, unlike foods, early contact with environmental allergens can make allergies worse. Research is the most robust when it comes to dust mites, according to AAAAI, which suggests working to control dust mites early to prevent allergy problems. Some solutions to control environmental allergens recommended in the guidance include:

Pet are different, though, according to AAAAI, with recent research suggesting that early exposure to pets can actually help protect children from developing allergies.

When You Need Help

The AAAAI also offered guidance on when to get help and where. If possible, the organization recommends finding an allergist specifically, as they have received specialized training in allergy and immunology. Allergy testing by a specialist can give detailed information about an allergy, and the best methods for treatment, according to AAAAI. On the other hand, AAAAI recommends against massive allergy screening tests done in retail sites, applied kinesiology, or testing through muscle relaxation, cytotoxicity testing, skit titration, provocative and neutralization testing, or sublingual provocation.

Kari Christine Nadeau, MD, PhD, Naddisy Foundation Endowed Professor of Medicine and Pediatrics and director of the Sean N. Parker Center for Allergy and Asthma Research at Stanford University in Palo Alto, California says its important that advice be given on science and epidemiological studies. In terms of allergy prevention, research studies show that a diversification of diets with a variety of proteins from different food sources introduced all at oncerather than staged as suggested by AAAAIcan decrease the risk of allergy and asthma development.

There are a number of other tips she offers for allergy prevention, including:

Nadeau also makes it clear that vaccination avoidance is not a prevention strategy for allergens, and that allergy prevention can begin at any age.

Reference

1. American Academy of Allergy, Asthma & Immunology. Prevention of allergies and asthma in children. Reviewed September 28, 2020. Accessed December 2, 2020. https://www.aaaai.org/conditions-and-treatments/library/allergy-library/prevention-of-allergies-and-asthma-in-children.

Read this article:
Allergy experts weigh in on prevention strategies - Contemporary Pediatrics

Read More...

NIH Statement on World AIDS Day 2020 | National Institutes of Health – National Institutes of Health

Friday, December 4th, 2020

News Release

Tuesday, December 1, 2020

We reflect both on the remarkable progress that has been made against HIV as well as the considerable challenges that remain.

Today on World AIDS Day, we reflect both on the remarkable progress that has been made against HIV as well as the considerable challenges that remain. We now have highly effective HIV treatment and prevention methods, and work is underway to address the remaining challenges in delivering these tools to the people who need them most, as well as to develop new interventions. The National Institutes of Health continues to advance rigorous, innovative research to prevent new HIV transmissions and improve the health of people with HIV worldwide.

This year the coronavirus disease 2019 (COVID-19) pandemic is creating great concern and uncertainty for people everywhere, including those affected by HIV. Notably, lessons we learned from involving affected communities in HIV research planning and implementation are informing our response to this new pandemic. NIH also is leveraging its HIV research infrastructure and expertise to conduct critical clinical trials evaluating investigational vaccines and monoclonal antibodies for COVID-19 prevention, as well as a variety of potential COVID-19 therapeutics.

In the face of the challenges posed by COVID-19, our work to address HIV has not slowed, reflecting the U.S. Government theme for this years World AIDS DayEnding the HIV Epidemic: Resilience and Impact and the theme for NIHs observance Science and Community: Working Together to Prepare for the Unexpected. We applaud the resilience of the HIV clinical trial participants, researchers, health care professionals, advocates and other members of the global community who are continuing their work to advance HIV research.

If current HIV treatment and prevention methods could be optimally implemented, an end to the HIV epidemic is feasible. This year, NIH awarded approximately $10 million to support implementation science research to advance the goals of the Ending the HIV Epidemic: A Plan for America initiative, which aims to reduce new HIV diagnoses in the United States by at least 90% by 2030.

Achieving a durable end to the HIV pandemic also will require continued development of new and improved HIV prevention and treatment tools that are safe, effective, scalable and desirable to diverse global populations. In a landmark advance this year, two large-scale clinical trials found that a long-acting form of the antiretroviral drug cabotegravir injected once every eight weeks was safe and more effective than daily oral pre-exposure prophylaxis at preventing HIV acquisition among cisgender women and cisgender men and transgender women who have sex with men. These results mark the first time a systemic, long-acting form of HIV prevention has been conclusively demonstrated to be highly effective.

Other forms of long-acting HIV prevention modalities under investigation include intravaginal rings, implants and antibodies. The adoption of a positive scientific opinion on the dapivirine vaginal ring by the European Medicines Agency this year and subsequent prequalification by the World Health Organization marked pivotal steps toward expanding HIV prevention choices for women. If approved by regulatory agencies,the monthly ring would provide women in developing countries with a discreet long-acting HIV prevention option that they control.

Development of a safe and effective HIV vaccine remains a top priority, and notably, certain platforms used todevelop COVID-19 vaccine candidatesemployed the structural biology techniques used in HIV vaccinology. Two ongoing clinical trials for HIV vaccines, Imbokodo and Mosaico, are evaluating an experimental HIV vaccine regimen designed to protect against a wide variety of global HIV strains. Results expected soon from two other clinical trials, evaluating intravenous infusions of a broadly neutralizing antibody for HIV prevention, will provide key insights for further development of antibody-based HIV prevention tools and ultimately a vaccine.

Thanks to extraordinary advances in antiretroviral therapy, many people with HIV can control the virus by taking just one pill each day. However, adhering to daily pills can be challenging. Researchers therefore are pursuing long-acting treatments that would allow a person with HIV to keep the virus suppressed without daily medication, as well as strategies to completely eradicate HIV from the body.

A few exceptional clinical scenarios have provided proof that HIV can be cured, including that of Timothy Ray Brown. Brown was widely recognized as the first person cured of HIV and for inspiring and advocating for scientists and communities worldwide to advance HIV cure research.Sadly, he died of leukemia in September 2020; however, his legacy lives on in the robust HIV cure agenda that researchers are pursuing today.

Even when HIV is well-controlled with treatment, people living with the virus are at heightened risk for co-infections and comorbidities.Tuberculosis remains the leading cause of death globally for people with HIV. Researchers recently reported thata new four-month treatment regimen is as safe and effective as the standard six-month regimen for drug-susceptible tuberculosis, a finding that has the potential to offer an additional tuberculosis treatment option that may be more convenient.

People with HIV also are more likely to experience noninfectious comorbidities such as heart disease, kidney disease and certain cancers. In order to successfully address these comorbidities, a robust research agenda is required to better understand how these conditions develop and to evaluate appropriate treatments. In this regard, the global REPRIEVE clinical trial that is focused on HIV and heart disease is teaching us about the many long-term health effects of HIV. The trial recently began gathering data to assess the impact of COVID-19 on people with HIV.

As we reflect today on our progress, we also look forward to new HIV research advances. To guide these efforts, NIH, through the Office of AIDS Research, recently released a 5-year strategic plan for HIV and HIV-related research. Yesterday, NIAID named the four HIV clinical trials networks that will conduct innovative clinical research in the United States and internationally over the next seven years to accelerate progress against the pandemic.

It is essential to work closely with communities and advocates to develop HIV prevention and treatment strategies that suit the diverse needs, preferences and desires of people with or at risk for HIV worldwide. It also is critical that we continue efforts to nurture the next generation of HIV investigators and ensure that diverse voices are represented. Together, we can identify the optimal strategies to improve the health of those with HIV, prevent new cases, and ultimately, end the pandemic.

NIAID conducts and supports research at NIH, throughout the United States, and worldwide to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID website.

About the National Institutes of Health (NIH):NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.

NIHTurning Discovery Into Health

###

More:
NIH Statement on World AIDS Day 2020 | National Institutes of Health - National Institutes of Health

Read More...

HIV Prevention Trials Network Awarded US National Institutes of Health Funding to Continue Research Agenda – GlobeNewswire

Friday, December 4th, 2020

DURHAM, N.C., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Drs. Myron S. Cohen and Wafaa M. El-Sadr, principal investigators of the HIV Prevention Trials Network (HPTN), in collaboration with FHI 360, have received a seven-year award from the U.S. National Institutes of Health as part of the next funding cycle (2020-2027) for the Network. The core and protocol-specific funding will enable the HPTN to continue its HIV prevention research efforts focused on developing new biomedical prevention methods and optimizing the integration of proven biomedical, behavioral and structural interventions to achieve high-effectiveness and impact.

During this new funding cycle, the HPTN will focus on the following four priority areas:

The HPTN will also continue as a partner in the COVID-19 Prevention Network (CoVPN). The recently-formed CoVPN evaluates biological agents, including vaccines and monoclonal antibodies, to prevent COVID-19.

In the absence of an HIV vaccine, effective non-vaccine prevention tools and strategies have become critically important, saidDr.Cohen, HPTN principal investigator and director of the Institute for Global Health at the University of North Carolina at Chapel Hill. This tenet is at the core of the HPTNs mission, moving forward research to identify biomedical interventions and integrated strategies that help reduce the global incidence of HIV.

Recognizing the challenges of long-term adherence to daily oral pre-exposure prophylaxis (PrEP), the HPTN has intensely pursued research to evaluate the safety and efficacy of long-acting injectable cabotegravir (CAB LA) for PrEP. Future approaches may include the use of implants, patches, and microneedles to deliver CAB LA and/or other long-acting ARVs. Combining ARV-based prevention tools that protect against HIV acquisition with efficacious contraceptive agents is compelling for persons who desire contraception and HIV prevention. Combinations of monoclonal antibodies will be evaluated for their potential to prevent HIV acquisition.

We recognize that demonstrating the efficacy of a new agent is the first step in a critical research trajectory, saidDr.El-Sadr,HPTN principal investigator,director of ICAP, and professor of epidemiology and medicine at Columbia University in New York. Achieving impact requires reaching and engaging diverse populations and achieving high uptake and adherence with prevention methods, compelling the need for integration of biomedical with behavioral and structural interventions.

FHI 360, a nonprofit human development organization, has been the leadership and operations center for the HPTN for more than 15 years and will continue to serve that role. FHI 360 is based in Durham, NC.

FHI 360 is committed to HIV prevention efforts as we all work towards reducing the rate of new HIV infections in populations deemed at greatest risk around the world, said Dr. Nirupama Sista, director of the HPTN Leadership and Operations Center at FHI 360.

About the HPTN

The HIV Prevention Trials Network (HPTN) is a worldwide collaborative clinical trials network that brings together investigators, ethicists, community members, and other partners to develop and test the safety and efficacy of interventions designed to prevent the acquisition and transmission of HIV. The U.S. National Institute of Allergy and Infectious Diseases, the U.S. National Institute of Mental Health, Office of The Director,the U.S. National Institute on Drug Abuse, and the Eunice Kennedy Shriver National Institute of Child Health and Human Development, all part of the U.S. National Institutes of Health,co-fund the HPTN. The HPTN has collaborated with more than 85 clinical research sites in 19 countries to evaluate new HIV prevention interventions and strategies in populations with a disproportionate HIV burden. The HPTN research agenda more than 50 trials ongoing or completed with over 161,000 participants enrolled and evaluated is focused primarily on discovering new HIV prevention tools and evaluating integrated strategies, including biomedical interventions combined with behavioral risk reduction interventions and structural interventions. For more information, visit hptn.org.

Media inquiries: Eric Miller, +1.919.384.6465; emiller@fhi360.org

Excerpt from:
HIV Prevention Trials Network Awarded US National Institutes of Health Funding to Continue Research Agenda - GlobeNewswire

Read More...

Medical Equipment Maintenance Market Research Report by Device Type, by Service Type, by Service Provider, by End-user – Global Forecast to 2025 -…

Friday, December 4th, 2020

New York, Dec. 02, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Medical Equipment Maintenance Market Research Report by Device Type, by Service Type, by Service Provider, by End-user - Global Forecast to 2025 - Cumulative Impact of COVID-19" - https://www.reportlinker.com/p05993403/?utm_source=GNW

The Global Medical Equipment Maintenance Market is expected to grow from USD 25,687.34 Million in 2019 to USD 47,861.28 Million by the end of 2025 at a Compound Annual Growth Rate (CAGR) of 10.92%.

Market Segmentation & Coverage:This research report categorizes the Medical Equipment Maintenance to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Device Type, the Medical Equipment Maintenance Market studied across Dental Equipment, Electro-Medical Equipment, Endoscopic Device, Imaging Equipment, Life Support Devices, and Surgical Instrument.

Based on Service Type, the Medical Equipment Maintenance Market studied across Corrective Maintenance, Operational Maintenance, and Preventive Maintenance.

Based on Service Provider, the Medical Equipment Maintenance Market studied across In-house Maintenance, Independent Service Organizations (ISOs), Multi-vendor OEMs, Original Equipment Manufacturers (OEMs), and Single-vendor OEMs.

Based on End-user, the Medical Equipment Maintenance Market studied across Private-sector Organizations and Public-sector Organizations.

Based on Geography, the Medical Equipment Maintenance Market studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas region surveyed across Argentina, Brazil, Canada, Mexico, and United States. The Asia-Pacific region surveyed across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, South Korea, and Thailand. The Europe, Middle East & Africa region surveyed across France, Germany, Italy, Netherlands, Qatar, Russia, Saudi Arabia, South Africa, Spain, United Arab Emirates, and United Kingdom.

Company Usability Profiles:The report deeply explores the recent significant developments by the leading vendors and innovation profiles in the Global Medical Equipment Maintenance Market including Abbott Laboratories, Agfa-Gevaert Group by Dedalus Holding S.p.A., Alpha Source Inc., Alpha Source, Inc., B. Braun Melsungen AG, Boston Scientific Corporation, Canon Inc., Drgerwerk AG & Co. KGaA, Edwards Lifesciences Corp, FUJIFILM Holdings Corporation, General Electric Company, Johnson & Johnson, Karl Storz GmbH & CO. KG, Koninklijke Philips N.V., Medtronic PLC, Olympus Corporation, Samsung Medison Co., Ltd., Siemens Healthineers, Stryker Corporation, and Terumo Corporation.

FPNV Positioning Matrix:The FPNV Positioning Matrix evaluates and categorizes the vendors in the Medical Equipment Maintenance Market on the basis of Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.

Competitive Strategic Window:The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies. The Competitive Strategic Window helps the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. During a forecast period, it defines the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth.

Cumulative Impact of COVID-19:COVID-19 is an incomparable global public health emergency that has affected almost every industry, so for and, the long-term effects projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlaying COVID-19 issues and potential paths forward. The report is delivering insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecast, considering the COVID-19 impact on the market.

The report provides insights on the following pointers:1. Market Penetration: Provides comprehensive information on the market offered by the key players2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes the markets3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, and manufacturing capabilities of the leading players5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and new product developments

The report answers questions such as:1. What is the market size and forecast of the Global Medical Equipment Maintenance Market?2. What are the inhibiting factors and impact of COVID-19 shaping the Global Medical Equipment Maintenance Market during the forecast period?3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Medical Equipment Maintenance Market?4. What is the competitive strategic window for opportunities in the Global Medical Equipment Maintenance Market?5. What are the technology trends and regulatory frameworks in the Global Medical Equipment Maintenance Market?6. What are the modes and strategic moves considered suitable for entering the Global Medical Equipment Maintenance Market?Read the full report: https://www.reportlinker.com/p05993403/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

See the original post:
Medical Equipment Maintenance Market Research Report by Device Type, by Service Type, by Service Provider, by End-user - Global Forecast to 2025 -...

Read More...

Dan Trigub left Uber Health to start a new healthcare venture. Here is what he’s working on – FierceHealthcare

Friday, December 4th, 2020

In his two years at Uber Health, Dan Trigub worked to expand access to medical transportation, and, now, he's focused on building aunique approach to home health.

Trigub and co-founder Inna Plumb have launched MedArrive as a new care management platform that enables healthcare providers and payers to extend services into the home.The startup bridges the virtual care gap by integrating physician-led telemedicine with hands-on care from a network of trusted EMS professionals, improving patient outcomes while empowering an underutilized segment of healthcare workers, according to the company.Backed by Redesign Health, MedArrive banked a $4.5 million seed round co-led by Kleiner Perkins and Define Ventures. In connection with the investment, Annie Case, principal at Kleiner Perkins, and Lynne Chou O'Keefe, founder and managing partner at Define Ventures, will both join the MedArrive board of directors.

Based in NewYork City, Redesign Health is aventure studio and holding company incubating tech-enabled healthcare businesses.

Driving Engagement in an Evolving Healthcare Ecosystem

Deep-dive into evolving consumer expectations in healthcare today and how leading providers are shaping their infrastructure to connect with patients through virtual care.

RELATED:Mayo, Intermountain navigate 'Wild West' of starting Hospital at Home during COVID-19 pandemic

Theinjection of capital will enable MedArrive to continue building its platform, grow its team of industry experts and drive the expansion of key healthcare provider partnerships across the country. With an initial focus on the Florida market, the team expects to expand quickly and effectively over the coming months.

The COVID-19 pandemic has placed additional stress on the health system, with patients avoiding clinics, delaying preventive and critical care and facing financial strain.

"By working alongside communities of EMS professionals, providers, and payors to bring high-quality care into the home at a fraction of the cost of alternatives, MedArrives integrated solution is putting patients back at the center of care," said Trigub, CEO of MedArrive.

Now more than ever, as we continue battling a global pandemic, patients deserve healthcare that is accessible, affordable and safe, he said.

Clinical care is moving more into the home, andtelemedicine is growing with thetailwinds of the COVID-19 pandemic, but it cant solve every health problem, Trigub told Fierce Healthcare.

"Our mission statement is to improve peoples lives to bring more humanity to healthcare, the physical touch and the contact, and telemedicine strips out the human side of care. By buildingthis platform andinfrastructure, we're connecting three stakeholders, patients, health plans andhealth systems and we're leveraging the most under-utilized workforce in healthcare, EMTs and paramedics," he said.

RELATED:Head of Uber Health leaving to launch new healthcare startupMedArrive taps into a capable workforce of EMS professionals so they can leverage the full scope of their training, earn supplemental income and diversify their day-to-day responsibilities. At the same time, patients using MedArrive are able to access trusted medical expertise from the safety of their homes and within their existing health systems, ultimately resulting in better patient outcomes, a better-utilized healthcare workforce and significant cost savings for patients and providers alike, according to the company.

Trigub, who left Lyft to become the head of Uber Health, announced in September that he was leaving the ride-share giant.

"Uber, at the end of the day, is not a healthcare-first organization. It's a massive company withamazing scale and reach. But there are lots of competing priorities. I wanted to give my fullattention toa pure healthcare business, and it's atremendous opportunity outside of a large tech environment that can have a lot of red tape and internal politics," he said.

While telehealth has helped to increase access to care, many care needs require in-person visits and diagnostics and often benefit from deeper insight into a patients experience at home,said Pat Songer, chief operating officer of Cascade Medical Hospital, executive director of the National EMS Management Association and adviser to MedArrive.

RELATED:Mayo Clinic teams with Medically Home to expand in-home hospital care

What MedArrive is doing is enabling this [EMS]workforce to utilize the full scope of their training and provide care in the home that cannot be done as effectively in a clinic setting, such as medication reconciliation, discharge instruction adherence, fall risk assessment, and collection of key SDoH and environmental data. This translates to better care experiences for patients and lower costs," Songer said.MedArrive partners can tap into anetwork of more than 20,000trusted emergency medical technicians and paramedics,with equal representation in rural and urban markets. This will be particularly critical for the company'spartners looking to distribute flu vaccines and, when available, a COVID-19 vaccine without overwhelming health systems, according to MedArrive executives.

Additional services include chronic condition management, transitional care, readmission prevention, urgent care and palliative care.

The COVID-19 pandemic has accelerated the shift to providing clinical care in patients' homes, according to Plumb, who has experience in private equity, finance and analytics.

"Care is moving into the home, but how can we do it cost-effectively? Byleveraging EMS and existing players in the market to deliver care in a cost-effective way, we can be active in both rural or urban environments," she said.

By leveraging virtual care and in-person care, MedArrive enables providers and payers to see what's going on in a patient's home to address social determinants of health and quality of life issues, Trigub said.

That taps into Trigub's experience atUber Health, where he led the company to form partnerships with Medicare Advantage plans to open up ride-sharing options. Uber Healthalso has put a focus on Medicaidas a key marketto focus on at-risk populations.

"What we can truly do here at MedArrive is have an outsized impact to helpdemocratize healthcare," he said.

Read more:
Dan Trigub left Uber Health to start a new healthcare venture. Here is what he's working on - FierceHealthcare

Read More...

Will the COVID-19 Vaccine Have Side Effects? Heres What Doctors Know so Far – Prevention.com

Friday, December 4th, 2020

Development of the COVID-19 vaccine is ongoing. Currently, two major vaccines pending approval by the FDA have been tested in more than 73,000 people in stage 3 clinical trials. While there are minor reported side effects, a vaccine wouldnt be approved by public health experts unless they felt confident its as safe as possible. While there are still some unknowns, the COVID-19 vaccine will in no way give you COVID-19.

Once a distant dream, the coronavirus vaccine is now a soon-to-be reality. In fact, the first doses could be distributed within two weeks, the nations governors were told during a conference call with the White House Coronavirus Task Force on Nov. 30.

Pharmaceutical giants Pfizer and Moderna have both submitted applications for an Emergency Use Authorization (EUA) with the Food and Drug Administration (FDA) for their respective vaccine candidates, both of which are reported to be more than 90% effective at preventing COVID-19 in participants in stage three clinical trials. Pfizer has included 43,538 people in its study, while Moderna has reported more than 30,000 participants.

The Centers for Disease Control and Preventions (CDC) Advisory Committee on Immunization Practices also held an emergency meeting on Dec. 1, and officially confirmed that healthcare workers and elderly residents of long-term care facilities will be the first to receive the vaccine once one is authorized.

While things are moving quickly, experts predict that most people wont have access to the vaccine, both of which will require two doses, until the late spring. Still, its only natural to have questions about how the vaccine works, what kind of potential side effects it could cause, and why its so important to get one. Heres everything we know so far.

Pending EUAs from the FDA, there will hopefully be two different vaccines available for COVID-19 by the end of the year. They both contain similar ingredients, just packaged differently, says infectious disease expert Amesh A. Adalja, M.D., senior scholar at the Johns Hopkins Center for Health Security.

Both vaccines use messenger RNA (mRNA), a new type of vaccine that encodes a part of the spike protein gene in SARs-CoV-2, a.k.a. novel coronavirus. This is the part of the virus responsible for its unique crown-like structure. The vaccine does not inject inactive virus into your body, but rather uses pieces of genetic material from SARs-CoV-2.

Heres how it works: mRNA gives your cells instructions to develop a protein that is similar to the novel coronavirus spike protein, according to the CDC. When your immune system recognizes that new protein as a foreign invader, it mounts an immune response to fight off what it interprets as an infection, and you develop antibodies specific to SARs-CoV-2. Your body eliminates the protein and the mRNA, but those antibodies stick around to help protect your from future COVID-19 infection. (Its important to note that mRNA does not alter your DNA, per the CDC.)

The two vaccines developed are the first of their kind. There have never been mRNA vaccines before, Dr. Adalja says.

Of course, there are other components as well. A vaccine has got to have materials in it to make sure that it is stable and can really function, says William Schaffner, M.D., an infectious disease specialist and professor at the Vanderbilt University School of Medicine. No vaccine is just purely the antigen. (An antigen is any substance that causes your immune system to produce antibodies to it.)

The actual ingredients in both vaccines havent been released yet, but likely will be once they are approved, Dr. Adalja says. However, many vaccines contain ingredients like preservatives (to prevent contamination), adjuvants like aluminum salts (to help boost the bodys response to the vaccine), and stabilizers like sugar or gelatin (to keep the vaccine effective after its manufactured), per the CDC.

The COVID-19 vaccine works completely differently than the yearly flu vaccine. The flu shot gives you an inactivated virus, Dr. Adalja explains. From there, the vaccine causes antibodies to develop in your body about two weeks after you get the shot, per the CDC. Those antibodies then help protect you against infection with the strains of the flu that are used to make the vaccine for that season.

The coronavirus vaccine, on the other hand, gives you a snippet of a gene, not an inactive virus, Dr. Adalja says.

You also need to get two shots of the current coronavirus vaccinestypically three to four weeks apartwhile the flu vaccine is just one shot a year, Dr. Schaffner says. Its unclear at this point if people will need the COVID-19 vaccine each year, he says. There are single-dose vaccines in the works as well, including one from Johnson & Johnson, which recently reached phase 3 of it clinical trial.

Details on the vaccines and their safety data havent been presented to the general public yet, but they will be once they receive EUAs from the FDAand before you would be given your first dose, Dr. Schaffner says. Since healthcare workers will be offered the vaccine first, your primary care physician can offer information to you based on personal experience, as well as data.

So far, what weve seen in the animal data and data from phases 1, 2, and 3 [human] trials shows a favorable safety profile, Dr. Adalja says.

Each vaccine is slightly different but, in general, experts say you may experience the following side effects with either COVID-19 vaccine:

This is similar to what youd expect with the flu vaccine, says Thomas Russo, M.D., professor and chief of infectious disease at the University at Buffalo in New York. [The side effects] usually only last a day or so. Theyre not serious or concerning. For example, the flu shot can also cause arm soreness, swelling at the injection site, a low-grade fever, and other side effects as the body starts to mount an immune response.

However, because the COVID-19 vaccines are so new, long-term side effects are not yet fully understood. Dr. Russo notes that vaccine makers, as well as the FDA, will continue to gather detailed data after a vaccine is released to the general public.

Moderna shared in mid-November that the following side effects were the most common among patients in its trial:

Pfizer shared that the following side effects happened in some patients:

Just like the flu shot cant give you the flu, the COVID-19 vaccine will not give you COVID-19. These side effects basically show that the immune system is being primed, says Richard Watkins, M.D., an infectious disease and professor of internal medicine at the Northeast Ohio Medical University. Remember, your body is learning to mount a response to SARs-CoV-2, which can lead to symptoms like a fever.

Its also important to note that the second shot may cause more side effects than the first shot. We want to let everyone know that so theyre not disappointed or worried that they have COVID-19, Dr. Schaffner says.

Getting the vaccine has several benefits, Dr. Adalja says. The big one? We can safely establish herd immunity, so the population at large can be protected from the virus if a threshold of vaccination is reached. Its a tall order, as experts estimate that roughly 70% of people in the U.S. (200 million) need to be vaccinated to reach this level of protection for COVID-19 specifically. This is especially important for vulnerable, high-risk groups, like the elderly and immunocompromised.

Experts also say getting vaccinated will help protect you personally from contracting COVID-19 or from having severe complications of the virus if you do happen to contract it.

When the vaccine is available to you, its crucial that you get it. At this point, one in 200 people who get COVID die, Dr. Watkins says. The benefit greatly outweighs the risks.

Go here to join Prevention Premium (our best value, all-access plan), subscribe to the magazine, or get digital-only access.

This content is created and maintained by a third party, and imported onto this page to help users provide their email addresses. You may be able to find more information about this and similar content at piano.io

Read more:
Will the COVID-19 Vaccine Have Side Effects? Heres What Doctors Know so Far - Prevention.com

Read More...

Global Next Generation Sequencing Market (2020 to 2026) – Growth, Trends, Competitive Landscape, and Forecasts – GlobeNewswire

Friday, December 4th, 2020

Dublin, Dec. 03, 2020 (GLOBE NEWSWIRE) -- The "Global Next Generation Sequencing Market: Growth, Trends, Competitive Landscape, and Forecasts" report has been added to ResearchAndMarkets.com's offering.

The global next-generation sequencing market is expected to grow at a CAGR of around 17.5% during 2020-2026. Next-generation sequencing is also known as high-throughput sequencing. It is the process of determining the sequence of nucleotides in a section of the DNA. It includes procedures such as sequencing by ion semiconductor sequencing, synthesis (SBS), nanopore sequencing and single-molecule real-time (SMRT) sequencing. It is a cost-effective solution that offers precise results with high accuracy and speed. This enables the analysis of millions of DNA molecules simultaneously, which facilitates research in the fields of personalized and genetic medicines, agriculture and animal research, and clinical diagnostics.

Market Drivers

Market Challenges

Report's Scope

The global next-generation sequencing market report elucidates key industry trends, industry dynamics along with the quantitative analysis of the report. The report presents a clear picture of the global next-generation sequencing market by segmenting the market based on sequencing type, product type, technology, application, end user, and region. We believe that this report will aid the professionals and industry stakeholders in making informed decision.

Key Topics Covered:

1. Preface1.1 Report Description1.1.1 Objective of the Study1.1.2 Target Audience1.1.3 USP & Key Offerings1.2 Report's Scope1.3 Research Methodology1.3.1 Phase I - Secondary Research1.3.2 Phase II - Primary Research1.3.3 Phase III - Expert Interviews1.3.4 Assumptions

2. Executive Summary

3. Global Next Generation Sequencing Market3.1 Introduction3.2 Market Drivers & Challenges

4. Global Next Generation Sequencing Market Analysis4.1 Market Portraiture4.2 Market by Sequencing Type4.3 Market by Product Type4.4 Market by Technology4.5 Market by Application 4.6 Market by End User4.7 Market by Region 4.8 Impact of COVID-19

5. Global Next Generation Sequencing Market by Sequencing Type 5.1 Market Overview5.2 Whole Genome Sequencing5.3 Targeted Resequencing5.4 Whole Exome Sequencing5.5 RNA Sequencing5.6 CHIP Sequencing5.7 De Novo Sequencing5.8 Methyl Sequencing5.9 Others

6. Global Next Generation Sequencing Market by Product Type 6.1 Market Overview6.2 Instruments6.3 Reagents and Consumables6.4 Software and Services6.5 Others

7. Global Next Generation Sequencing Market by Technology Type 7.1 Market Overview7.2 Sequencing by Synthesis7.3 Ion Semiconductor Sequencing7.4 Single-Molecule Real-Time Sequencing7.5 Nanopore Sequencing7.6 Others

8. Global Next Generation Sequencing Market by Application8.1 Market Overview8.2 Drug Discovery and Personalized Medicine8.3 Genetic Screening8.4 Diagnostics8.5 Agriculture and Animal Research8.6 Bioinformatics8.7 Others

9. Global Next Generation Sequencing Market by End User9.1 Market Overview9.2 Academic Institutes & Research Centers9.3 Hospitals & Clinics9.4 Pharmaceutical & Biotechnology Companies9.5 Others

10. Global Next Generation Sequencing Market by Region10.1 Market Overview10.2 Europe10.2.1 Germany10.2.2 United Kingdom10.2.3 France10.2.4 Italy10.2.5 Spain10.2.6 Netherlands10.2.7 Russia10.2.8 Rest of the Europe10.3 North America10.3.1 United States10.3.2 Canada10.4 Asia Pacific10.4.1 China10.4.2 Japan10.4.3 South Korea10.4.4 Australia10.4.5 India10.4.6 Indonesia10.4.7 Rest of the Asia Pacific10.5 Latin America10.5.1 Mexico10.5.2 Brazil10.5.3 Argentina10.5.4 Rest of Latin America10.6 Middle East & Africa10.6.1 Saudi Arabia10.6.2 Turkey10.6.3 United Arab Emirates10.6.4 Rest of Middle East & Africa

11. SWOT Analysis

12. Porter's Five Forces

13. Market Value Chain Analysis

14. Competitive Landscape14.1 Competitive Scenario14.2 Company Profiles14.2.1 10x Genomics14.2.2 Agilent Technologies Inc.14.2.3 Becton Dickinson and Company14.2.4 BGI Group14.2.5 Eurofins Scientific14.2.6 F. Hoffmann-La Roche AG14.2.7 Illumina Inc.14.2.8 Genewiz14.2.9 Macrogen Inc.14.2.10 Oxford Nanopore Technologies14.2.11 Pacific Biosciences14.2.12 Perkinelmer Inc.14.2.13 Thermo Fisher Scientific Inc.14.2.14 Qiagen N.V.14.2.15 Genapsys Inc.

For more information about this report visit https://www.researchandmarkets.com/r/j561mc

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Continued here:
Global Next Generation Sequencing Market (2020 to 2026) - Growth, Trends, Competitive Landscape, and Forecasts - GlobeNewswire

Read More...

Native American Ancestry Associated With Increased EGFR Mutations – Technology Networks

Friday, December 4th, 2020

Bottom Line: Among patients with lung cancer from Latin America, genomic and ancestry analyses revealed that Native American ancestry was associated with increased mutations in the EGFR gene, independent of smoking status.

Journal in Which the Study was Published: Cancer Discovery, a journal of the American Association for Cancer Research

Author: Matthew Meyerson, MD, PhD, director of the Center for Cancer Genomics at Dana-Farber Cancer Institute in Boston; professor of genetics and medicine at Dana-Farber Cancer Institute and Harvard Medical School; and an Institute Member of the Broad Institute of MIT and Harvard in Cambridge, Massachusetts

Background: "Lung cancer is the leading cause of cancer mortality, both in the United States and globally, and understanding inherited risk factors for this disease may help us to identify populations that would benefit from increased screening efforts," said Meyerson.

"Previous work has demonstrated that EGFR-mutant lung cancer is more common among populations from East Asia compared with populations from North America or Europe, about 50 percent versus 10 percent of lung cancer cases, respectively," said Meyerson. "But it is not clear whether the ethnic difference in EGFR-mutant lung cancer is due to environmental or genetic factors," he added.

How the Study was Conducted & Results: Meyerson and colleagues analyzed samples from 1,153 patients with lung cancer from Latin America. Of them, 601 were from Mexico and 552 were from Colombia, and 499 patients self-reported as non-smokers. Through genomic analysis of tumor samples, the researchers identified somatic mutations in EGFR, KRAS, and other target genes.

Using a new method developed by Jian Carrot-Zhang, PhD, and Alexander Gusev, PhD, the researchers also performed ancestry analyses from tumor samples in this admixed population. Global ancestry analysis was performed to measure proportions of African, European, and Native American ancestry across the genome. Additionally, local ancestry analysis was performed, which evaluates genetic ancestry at a particular chromosomal location. Because local ancestry only evaluates a small portion of the genome, there is less potential for observed associations to be confounded by environmental exposures or socioeconomic status, which may be seen in global ancestry analyses, Meyerson explained.

Using the genomic and ancestry data, the researchers assessed the associations of somatic mutations in target genes and global ancestry groups within a single admixed population. After adjusting for a variety of factors, including self-reported smoking status and sample-specific tumor mutational burden, the researchers found that global Native American ancestry was positively correlated with mutations in the EGFR gene. Further, the researchers found that Native American ancestry was predominantly associated with oncogenic mutations in the EGFR gene, but not with non-oncogenic mutations.

Meyerson and colleagues then stratified patients by their self-reported smoking status and evaluated the association between global ancestry and mutations in target genes. In both never smokers and smokers, global Native American ancestry was associated with mutations in the EGFR gene, suggesting that the genomic differences associated with Native American ancestry are independent of smoking status.

"Smoking increases the risk for KRAS-mutant lung cancers, while patients with lung cancer who are non-smokers more often develop EGFR-mutant lung cancer," Meyerson said. "However, we show in our study that EGFR-mutant lung cancer is also elevated among smokers with Native American ancestry."

The researchers next developed a local Native American ancestry risk score to evaluate the association of ancestry with EGFR mutation frequency across multiple distinct sites in the genome. They found that the correlation between ancestry and increased mutation frequency in the EGFR gene was stronger at the local genome level than the global genome level. "These results suggest that germline genetics-in addition to environmental factors or socioeconomic status-may have an influence on the risk of EGFR-mutant lung cancer among those with Native American ancestry," Meyerson said.

The study was jointly led by Meyerson; by Gusev, an assistant professor of medicine at Dana-Farber and Harvard Medical School; by Andres F. Cardona, MD, of the Clinica del Country/Foundation for Clinical and Applied Cancer Research (FICMAC) in Bogota, Colombia; and by Oscar Arrieta, MD, head of Thoracic Oncology at the Instituto Nacional de Cancerologia in Mexico City. Carrot-Zhang, a postdoctoral research fellow at Dana-Farber Cancer Institute and Broad Institute, and first author of the study, developed computational methods with Gusev and performed the bulk of the computational analyses.

Author's Comments: "Many lung cancers are now treatable with targeted therapy or immunotherapy," Meyerson continued. "It is very important for patients with lung cancer to undergo somatic genetic testing to determine which treatments are most likely to be effective for their particular cancer."

Study Limitations: Limitations of the study include a small sample size, which Meyerson noted precluded the identification of the specific gene or site in the germline that is associated with increased somatic EGFR mutations among those with Native American ancestry. Further, the researchers only tested known hotspot mutations and protein truncating mutations in lung cancer driver genes, and future work is needed to comprehensively characterize lung cancer genomes from Latin American patients, Meyerson said.

Funding & Disclosures: This study was supported by a Translational Research Award from the Stuart Scott Memorial Fund of the V Foundation and by the National Cancer Institute. Meyerson is an American Cancer Society Research Professor.

Meyerson is the scientific advisory board chair of OrigiMed and an inventor of patents licensed to LabCorp for the diagnosis of mutations to the EGFR gene, with pending patent applications on EGFR inhibitors. Meyerson receives research funding from Bayer, Janssen, Novo Ventures, and Ono Pharmaceutical Co.

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Read this article:
Native American Ancestry Associated With Increased EGFR Mutations - Technology Networks

Read More...

Precision Medicine Market Poised to Grow at 11.5% By 20227 – GlobeNewswire

Friday, December 4th, 2020

OTTAWA, Nov. 30, 2020 (GLOBE NEWSWIRE) -- The global precision medicine market value surpassed USD 59.16 billion in 2019 and expected to reach USD 141.33 billion by 2027.

Precision medicine is an emerging approach of treatment and prevention of disease that takes into account the individual variability in environment, genes, and lifestyle for each person. This approach allows researchers and doctors to predict more precisely that which treatment and prevention strategies for a particular disease will work on the specified groups of people.

Although the term "precision medicine" is currently new to the consumers, the concept has been a part of healthcare industry for many years. For instance, a person who requires a blood transfusion is not given blood from any random donor; instead, the blood type of donor is matched with the recipient prior transfusion to reduce the risk of complications. Although examples can be found in various areas of medicine, the role of precision medicine in everyday healthcare is relatively limited. Researchers are significantly working to expand this approach in many areas of healthcare and health in the coming years.

Get the Sample Pages of Report for More Understanding@ https://www.precedenceresearch.com/sample/1085

Growth Factors

The advent of precision medicine has significantly brought a paradigm shift in the drug delivery and diagnosis of the disease. The proliferation of sequencing methodologies, particularly Next Generation Sequencing (NGS), due to the increasing cost of sequencing and development of the Human Genome Project in the field of genomics is predicted to drive the market. NGS technology provides the data related to the patients genetic makeup along with response of drugs on the patient, thereby raising the development of precision medicine for the treatment of diseases. Moreover, NGS combined with Companion Diagnostics (CDx) is analyzed to play a significant role in the advancement of personalized therapeutics and diagnostics over the forecast period. Apart from the benefits offered by the precision medicine, they are highly expensive due to the application of high-end computational methods to examine individual genes projected to hinder the market growth.

Regional Snapshots

North America dominated the global precision medicine market with revenue share of nearly 40% in 2019 and expected to grow at an escalating pace during the forecast period. Technological advancement along with the presence of major players in the region contributes significantly towards the growth of the region. However, the Asia Pacific seeks to be the most opportunistic region in the precision medicine market owing to increasing cases of cancer and other diseases along with the health awareness among people.

View Full Report with Complete ToC@ https://www.precedenceresearch.com/precision-medicine-market

Report Highlights

Get Customization on this Research Report@ https://www.precedenceresearch.com/customization/1085

Key Players & Strategies

The global precision medicine market is highly competitive owing to the presence of major market participants. These market players are highly focused towards development and innovation of personalized products to upscale their position in the market. For instance, in October 2018, Qiagen announced to launch a novel RNA-seq library preparation solution for next-generation sequencing thereby expanding its user base and portfolio significantly. Similarly, other industry participants are also working prominently for advancement and innovation in the field of precision medicine.

Some of the key players operating in the market are Biocrates Life Sciences, TepnelPharma Services, Novartis, Qiagen, Quest Diagnostics, Menarini Silicon Biosystems, NanoString Technologies, Eagle Genomics, Pfizer, Intomics, Roche, and Teva Pharmaceutical among others.

Market Segmentation

By Technology

By Application

By End-Use

By Regional Outlook

Full Report is Ready | Buy this Premium Research Report@ https://www.precedenceresearch.com/checkout/1085

You can place an order or ask any questions, please feel free to contact at sales@precedenceresearch.com | +1 774 402 6168

About Us

Precedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally.

For Latest Update Follow Us:

https://www.linkedin.com/company/precedence-research/

Read the original post:
Precision Medicine Market Poised to Grow at 11.5% By 20227 - GlobeNewswire

Read More...

The Best At-Home DNA Test Kits for Ancestry and Health – Health.com

Friday, December 4th, 2020

Results include: Ethnicity estimate; Health predisposition reports; Carrier status reports; Wellness reports; Personal traits reports; Pharmacological compatibility

TellmeGen offers an ancestry plus health test that gives over 390 results. While the ancestry results arent as robust as competitors, the health component may be the most comprehensive at-home DNA test youll find. Youll receive information about your genetic predisposition to 100 diseases, carrier status for 88 inherited disorders, 150 characteristics of medication compatibility, and more than 50 personal traits. These personal traits are more meaningful than other tests that give information on hair growth or eye color; this test looks at likelihood of alcohol dependency, thyroid function, or preterm birth.

With TellmeGen, youll have access to a free medical forum where you can share your thoughts and ask questions of other users as well as the medical team. For an additional fee, you can request a consultation with a physician, genetic counselor, or nutritionist. Your results will be continually updated as new genetic science becomes available.

TellmeGen uses microarray technology (similar to 23andMe), which tests your DNA for certain variants of a gene known to be associated with a disease. The test doesnt give you information on every possible genetic variant that could cause the disease, only the most common. It is possible that you could have a genetic variant increasing your likelihood for the disease, even if the test report is negative.

Time to results: Four to six weeks

Price: $139

Information updates: Yes

Pros

Cons

Before you take a DNA test, ask yourself whether you really want to know some of the information that could become available to you.

People often find surprising information when they dig into their family historyinformation that affects not only themselves but their parents, siblings, or children. You may find a connection to a relative you didnt know existed or you could find that your genetic information is not linked to someone you thought was a blood relative. These could become issues you and your family grapple with for years to come.

Do you want to know if youre predisposed to an incurable disease such as Alzheimers or Parkinsons, or would you rather only know about diseases you can take action to prevent, such as Type II diabetes or high cholesterol? Depending on the type of test you choose, you may have to consider these questions as well, and your answer may affect your loved ones, too.

Make sure youre prepared for surprises and be certain you want to know the answers your test provides.

Originally posted here:
The Best At-Home DNA Test Kits for Ancestry and Health - Health.com

Read More...

Tevard Biosciences and Zogenix Announce Collaboration to Advance Novel Gene Therapies for Dravet Syndrome and Other Genetic Epilepsies – PRNewswire

Friday, December 4th, 2020

CAMBRIDGE, Mass. and EMERYVILLE, Calif., Dec. 3, 2020 /PRNewswire/ --Tevard Biosciences, a privately-held biotechnology company pioneering tRNA-based gene therapies, and Zogenix (Nasdaq: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that the companies have entered into a collaboration to identify and develop novel tRNA-based gene therapies for Dravet syndrome and other genetic epilepsies.

Under the collaboration, Tevard will utilize its two unique tRNA-based discovery platforms focused on mRNA Stabilization and Nonsense Codon Suppression to discover and advance novel drug candidates for the treatment of Dravet syndrome and other genetic epilepsies. Zogenix will further develop the candidates through advanced preclinical studies and clinical development, and be responsible for worldwide commercialization.

Zogenix is responsible for funding the collaboration and, under the terms of the agreement, Tevard will receive an initial collaboration payment of $10 million, of which approximately $5 million has previously been paid by Zogenix. Tevard will also receive $5 million in the form of a convertible note. Tevard is also eligible to receive additional development, regulatory and commercial-related milestone payments ranging from $70 million to $100 million for each program, as well as tiered royalties on future net global sales on any commercial products that result from the collaboration.

Tevard's unique tRNA technology platforms are designed to address underlying genetic mutations in a precise and regulated manner through the correction of nonsense mutations and the enhanced production of functional proteins. Together, these approaches hold promise to treat genetic disorders that are not well-suited to conventional gene replacement approaches.

"We are pleased to announce our collaboration with Zogenix, whose commitment to developing new treatments for Dravet syndrome and other genetic epilepsies is unparalleled," said Daniel E. Fischer, Co-founder, President, and Chief Executive Officer at Tevard Biosciences. "Tevard has assembled a team of leading experts focused on developing our breakthrough tRNA-based gene therapy platforms. Our collaboration with Zogenix will advance our mission to bring transformative gene therapy products to those living with Dravet and other rare and severe genetic disorders.

"We are thrilled to be working with an innovative company like Tevard to develop promising next-generation therapies," said Stephen J. Farr, Ph.D., President and Chief Executive Officer of Zogenix. "Through this important new collaboration, we have reinforced our long-term commitment to transforming the lives of rare epilepsy patients and their families, and look forward to sharing updates as our work together progresses."

About Dravet SyndromeDravet syndrome is a rare childhood-onset epilepsy marked by frequent debilitating seizures, lifelong developmental and motor impairments, and an increased risk of death (SUDEP). In addition to the catastrophic impact on the patient, the severity and unpredictability of the seizures, coupled with around-the-clock concern for the diagnosed child's safety and well-being, can present significant emotional and logistical challenges for parents and all members of the family.

About Tevard BiosciencesTevard Biosciences is a privately held biotechnology companypioneering tRNA-based gene therapiesto cure rare and severe genetic diseases with limited or no approved treatment options. Tevard was founded by MIT Professor and Whitehead InstituteFoundingMember Harvey Lodish, Ph.D., with life science entrepreneurs and executives Daniel Fischer and Warren Lammert, fathers of children with Dravet syndrome. The company is developing and applying two novel tRNA-based gene therapy platforms, co-invented by Professor Lodish with Johns Hopkins School of Medicine Professor Jeff Coller, Ph.D. and University of Iowa Professor Chris Ahern, Ph.D., for Dravet syndrome and other rare diseases caused by haploinsufficiency and/or nonsense mutations that are not amenable to traditional approaches to gene therapy. For more information, please visitwww.tevard.com.

About ZogenixZogenix is a global biopharmaceutical company committed to developing and commercializing therapies with the potential to transform the lives of patients and their families living with rare diseases. The company's first rare disease therapy, FINTEPLA (fenfluramine) oral solution has been approved by the U.S. FDA and received a positive CHMP opinion in Europe for the treatment of seizures associated with Dravet syndrome, a rare, severe childhood onset epilepsy. The company has two additional late-stage development programs underway: one for FINTEPLA for the treatment of seizures associated with Lennox-Gastaut syndrome, a different rare childhood-onset epilepsy and another for MT1621, an investigational novel substrate enhancement therapy for the treatment of TK2 deficiency, a rare genetic disorder. MT1621 is being developed through Modis Therapeutics, a Zogenix company.

Forward Looking Statements Zogenixcautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "indicates," "will," "intends," "potential," "suggests," "assuming," "designed," and similar expressions are intended to identify forward-looking statements. These statements include the potential that the use tRNA-based discovery platforms will result in the discovery and advancement novel drug candidates for the treatment of genetic epilepsies; and Zogenix's intention to develop any drug candidates discovered through tRNA-based discovery platforms. These statements are based on Zogenix's current beliefs and expectations. The inclusion of forward-looking statements should not be regarded as a representation byZogenixthat any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risks and uncertainties inherent in Zogenix's business, including, uncertainties related to pharmaceutical product development, including whether any drug candidate will be discovered; results from preclinical or clinical studies may not support the continued development or commercialization of any discovered drug candidate; delays or disruptions in Zogenix's or Tevard's business operations due to the COVID-19 pandemic and other risks described in Zogenix's prior press releases as well as in public periodic filings with theU.S. Securities & Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, andZogenixundertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

CONTACTS:

Tevard BiosciencesInvestors and MediaKaren L. Bergman for Tevard+1 (650) 575-1509[emailprotected]

ZogenixMelinda BakerSenior Director, Corporate Communications+1 (510) 788-8732[emailprotected]

InvestorsBrian RitchieManaging Director, LifeSci Advisors LLC+1 (212) 915-2578[emailprotected]

MediaStefanie TuckVice President, Porter Novelli+1 (978) 390-1394[emailprotected]

SOURCE Tevard Biosciences

Home

See original here:
Tevard Biosciences and Zogenix Announce Collaboration to Advance Novel Gene Therapies for Dravet Syndrome and Other Genetic Epilepsies - PRNewswire

Read More...

How COVID-19 highlights the uncertainty of medical testing – FierceBiotech

Friday, December 4th, 2020

Jacqueline Chu, M.D., considered the man with a negative coronavirus test on the other end of the phone, and knew, her heart dropping, that the test result was not enough to clear him for work.

The man was a grocery store clerkan essential workerand the sole earner for his family. A 14-day isolation period would put him at risk of getting fired or not having enough money to make rent that month. But he had just developed classic COVID-19 symptoms, and many others around him in Chelsea, Massachusetts, had confirmed cases. Even with the negative test, his chances of having the disease were too high to dismiss.

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the worlds leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

For many Americans, including clinicians like Chu, who specializes in primary care and infectious disease at Massachusetts General Hospital, the pandemic has forced difficult conversations about the limits of medical tests. It has also revealed the catastrophic harms offailing to recognize those limits.

People think a positive test equals disease and a negative test equals not disease, said Deborah Korenstein, M.D., who heads the general medicine division at Memorial Sloan Kettering Cancer Center in New York City. Weve seen the damage of that in so many ways with COVID.

National COVID-19 test shortages have emphasized testings critical role in containing and mitigating the pandemic, but these inconvenient truths remain: A test result is rarely a definitive answer, but instead a single clue at one point in time, to be appraised alongside other clues like symptoms and exposure to those with confirmed cases. The result itself may be falsely positive or negative, or may show an abnormality that doesnt matter. And even an accurate, meaningful test result is useless (or worse) unless its acted on appropriately.

These lessons are not unique to COVID-19.

Last year, David Albanese logged in to the online patient portal for his primary care doctors office and discovered that his routine screening test for the hepatitis C virus showed a positive result.

I never considered myself somebody whos in a high-risk category, said the 34-year-old Boston-area college administrator and adjunct history professor. But I just know that for a couple of days, I was really, really anxious about this test. I didnt know if I should be behaving differently based on it.

Within days, a confirmatory test showed Albanese did not actually have the potentially severe yet curable liver infection. Still, the memory of that false positive result gave him a new perspective on testing writ large. He had been skeptical of recommendations shifting breast cancer screening to older ages to reduce the psychological toll of false positives, but he said they made more sense after his own testing drama.

Isnt it better to do the screening regardless? he said he used to think. Now, I realize it is a little more complicated.

These false positives are especially common for screening tests like hepatitis C antibody tests and mammograms that look for medical problems in healthy people without symptoms. They are designed to cast a wide net that catches more people with the disease, known as the tests sensitivity, but also risks catching some without it, which lowers what is known as the tests specificity.

Though some degree of uncertainty is inherent in all medical decisions, clinicians often fail to share this with patients because its complicated to explain and unsettling and leaves doctors vulnerable to seeming uninformed, said Korenstein. Whats more, doctors are trained to seek definitive answers and can themselves struggle to think in probabilities.

High-tech diagnostic testing has led to this mirage of certainty, said Korenstein. Back in the day before there were MRIs and what not, I think, doctors were more cognizant of how often they were uncertain.

Enter COVID-19. Coupled with genuine uncertainty about an emerging disease and a political environment that has sown misinformation and rendered science partisan, the nuances of testing are too often lost at a time when they are particularly crucial to convey.

Jasmine Marcelin, M.D., who specializes in infectious disease at the University of Nebraska Medical Center, was concerned to see Nebraskans tested at statewide facilities get inconsistent results without a lot of guidance or explanation about what these results might mean. When she offers COVID testing, she said, she approaches it as she does any other medical decision, starting with a simple question: What do you want to learn from this test?

To answer this, it helps to know something about how coronavirus tests work and how well they do their jobs.

Many of the available tests are meant to tell you whether youre infected right now. For example, polymerase chain reaction tests like the one Chus patient received detect small traces of genetic material from the virus. But by some estimates, those tests have a false negative rate of up to 30%, meaning three out of 10 people who truly have the infection will test negative. This rate also varies based on who collects the sample, from which part of the body and when in the course of a possible infection.

Antigen tests look for viral proteins and are faster to analyze than the PCR, but also less accurate.

To know if youve already had COVID-19, the closest you can get is the COVID-19 antibody test. But the too-common interpretation is black and white: I had COVID-19, or I didnt. Here, again, the reality is more nuanced. The test checks your blood for antibodiesyour immune systems soldiers in the fight against the coronavirus. A negative antibody test could mean you were never infected with SARS-CoV-2, or it could mean that youre currently infected but havent yet built up that army, or that these defenses have already faded away.

A positive test, on the other hand, may have mistakenly detected antibodies to another, similar-looking virus. And, even if the test correctly shows you had COVID-19, its not yet clear whether this means youre protected from reinfection.

Yet, these shades of gray are difficult to internalize. Roy Avellaneda, the 49-year-old president of the Chelsea City Council, got the antibody test out of curiosity and could not help but see his positive result as what he called an immunity pass. I can act a little bit cavalier with it now, he said. Yes, Ill continue to wear a mask and so forth, but the fear is gone.

Korenstein said thats a common though worrisome reaction. Its really hard to expect the public to have a more nuanced understanding when even doctors dont, she said.

Some of the uncertainty around COVID-19 testing has abated as researchers learn more about the new disease. Early in the pandemic, healthcare providers retested patients with confirmed cases, looking for a negative PCR test to prove they were no longer infectious. But soon, epidemiologists discovered that a COVID-19 patient rarely infected others 10 or more days after first developing symptoms (or 20, in severe cases), even if the PCR test was picking up traces of thepresumably deadvirus weeks or even months after initial infection. So the Centers for Disease Control and Prevention and health systems adjusted their policies to clear patients on the basis of time rather than a negative test.

But while the desire for certainty in coronavirus testing is magnified by the rampant uncertainty in other facets of pandemic life, this is simply not something most medical tests can provide.

Kaiser Health News(KHN) is a national health policy news service. It is an editorially independent program of theHenry J. Kaiser Family Foundationwhich is not affiliated with Kaiser Permanente.

See original here:
How COVID-19 highlights the uncertainty of medical testing - FierceBiotech

Read More...

MLL Fusion Proteins Emerge as a Promising Target in AML – OncLive

Friday, December 4th, 2020

Novel agents that disrupt protein-protein interactions in the MLL network may be the key to unlocking new therapeutic avenues for patients with acute leukemias, which are characterized by diverse genetic and epigenetic alterations that are challenging to target, according to investigators.1

Early clinical data have demonstrated an antitumor effect of small molecule inhibitors directed at interactions of menin, a tumor suppressor protein, and MLL fusion proteins in acute myeloid leukemia (AML).2 One such agent, KO-539, is being investigated in 2 genetic subsets of AML: patients with rearrangements in KMT2A (also known as MLL1 or MLL) or with NPM1 mutations, which both promote leukemogenesis.

KMT2A(MLL) translocations are found in approximately 5% to 10% of patients with acute leukemias, including lymphoid, myeloid, or biphenotypic subtypes2; the 5-year survival rate for this population is approximately 35%.1 Over 30% of patients with AML have NPM1 mutations that, when they occur along with FLT3-ITD mutations, result in an overall survival rate of less than 50%.1

Investigators believe that menin is involved with a variety of cellular processes including aiding in the structural modification of MLL that stabilizes the bond between MLL and lens epithelium derived growth factor, a transcriptional coactivator believed to play a role in cancer.2 By causing a genetic disruption of the menin-MLL fusion protein interaction, they hypothesize, a novel agent could block the development of acute leukemia (Figure).3

In preclinical research, KO-539 prolonged survival compared with quizartinib, a FLT3 inhibitor, in 2 patient-derived xenograft models of NPM1/DNMT3/FLT3-mutant AML. In a confirmatory study, animals that were NPM1- and FLT3-mutant/DNMT3A wild-type and were treated with quizartinib relapsed by approximately day 35; those treated with KO-539 had no evidence of disease progression after 56 days.4

Although translocations of KMT2A(MLL) occur in approximately 3% of patients with AML, the mutational burden of these patients is far less than that of other cancer types; as a result, the translocations alone may result in the generation of the leukemic phenotype. Further, gene expression profiling has demonstrated overexpression of both HOXA9 and MEIS1, 2 oncoproteins thought to be critical for enhanced self-renewal in AML. Specifically, transcription of the HOXA9 and MEIS1 genes are dependent on KMT2A(MLL)-fusion protein binding to menin.5

The menin-MLL interaction seems to trigger the upregulation of certain leukemogenic or leukemia-promoting proteins, such as HOXA9 and MEIS1, said Amir T. Fathi, MD, in an interview with OncLive. [Developing] drugs that inhibit the leukemogenic signals can, in theory, lead to promotion of differentiation and maturation and response. Fathi is an associate professor of medicine at Harvard Medical School and director of the Leukemia Program at Massachusetts General Hospital, both in Boston.

Although KMT2A(MLL) and NPM1 alterations currently are the frontrunners as targets for in-human studies, Fathi suggested that, in time, investigators may learn more about efficacy in other subpopulations of patients with AML whose disease may be affected by epigenetic dysregulation from the menin-MLL interaction. If so, such findings may emerge as points of interest.

Other mutations that are seen in AML and myeloid malignancies, such as NPM1, DNMT3, EZH2, and others, appear to have their impact upstream from the menin-MLL, interaction, Fathi said. These alterations, too, can theoretically affect the menin-KMT2A interaction and complex and promote epigenetic dysregulation and leukemogenesis.

Because of the potential for broad efficacy, KO-539 is undergoing testing in a varied patient population in the phase 1 portion of the KOMET-001 trial (NCT04067336). We are assessing patients across a wide range of molecular subtypes to further define who may benefit from this class of targeted drug, explained Fathi, one of the leading investigators. We suspect that some patients with an NPM1 mutation or those with MLL rearrangements may be susceptible to response based on what we know from preclinical science, and we should study these populations carefully, but we are also assessing more broadly initially across AML to better characterize the other patient populations that may benefit.

KOMET-001 is the first in-human study of the menin-MLL inhibitor, which is being developed by Kura Oncology. The study will evaluate the safety and tolerability of escalating doses of KO-539 monotherapy for patients with relapsed and/or refractory AML.

Up until now, initial studies have been done extensively in preclinical models, said Eunice S. Wang, MD. If we extrapolate from some of our clinical models, we think that a dose of approximately 600 milligrams once per day would be effective, but because this is a first-in human study, we [followed] the typical phase 1 study design where we increase the dose.

Wang serves as chief of Leukemia Service, medical director of Infusion Services, at Roswell Park Comprehensive Cancer Center, and an associate professor in the Department of Medicine at Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo. She is scheduled to present preliminary data from the study during the 2020 American Society of Hematology Annual Meeting, which is being held in a virtual format December 5 to 8.

In an interview in advance of her presentation, Wang noted that investigators used a novel study design and started the first dose of KO-539 at 50 mg. KO-539 was administered orally once daily to patients in 28-continuous-day cycles and, as of data cutoff of August 10, 2020, 6 patients had proceeded through to the 200-mg dose. Following this, an expansion cohort of 3 patients at a 200 mg dose was initiated to better characterize the pharmacokinetics and exposure of KO-539.6

Early data show that KO-539 demonstrated biologic activity in 3 patients in the first 3 dose cohorts of 50 mg, 100 mg, and 200 mg. Tumor lysis syndrome was reported for 2 patients in the 50- and 200-mg cohorts. The patients had a KMT2A(MLL)-rearrangement and a TP53 mutation with a PICALM-AF10 fusion, respectively. The third patient treated at the 100-mg dose level had SETD2 and RUNX1 comutations and achieved a complete remission with confirmed negative minimal residual disease after 2 cycles of therapy. The patient remains on treatment.6

Although the study sample data are too small to reach conclusions, activity of the agent is promising. The complete remission data was very exciting, for a pill taken once a day for a patient who had multiple relapses, said Fathi. The responding patient did not have an MLL-translocation nor an NPM1-mutation, but there were other alterations that may have ultimate effects on the menin-MLL interaction and whose disease may thus have been susceptible to menin inhibition. It leaves open the door for the possibility to identify other groups of patients across AML who may benefit.

In safety data for 3 evaluable patients, no dose-limiting or dose-interrupting toxicities have been reported.6 Wang plans to present updated safety and efficacy data at the meeting.

Expansion cohorts are planned to further assess the safety and activity of KO-539 in an NPM1-mutant cohort and a KMT2A(MLL)-rearranged cohort. Right now, the expansion cohorts are designed to target subsets of patients with AML that have those specific mutations, said Wang. However, if we see evidence [of efficacy] in the early dose-escalation trials, we may consider trying to expand out [to other mutational subtypes] as well to a pool of patients with leukemia that are what we call mutation agnostic.

Theres still a lot of ground to go and patients to enroll, but there is a lot of opportunity to probe that signal a little bit more, to learn more, and to hopefully help these patients, Fathi said.

Another drug that aims to disrupt menin-MLL interactions is SNDX-5613, an oral inhibitor being developed by Syndax Pharmaceuticals under an FDA orphan drug designation for adults and pediatric patients with AML.7 The phase 1/2 AUGMENT-101 trial (NCT04065399) is testing the agent in patients with relapsed/refractory leukemias.

The study, which seeks to recruit 186 pediatric and adult patients, will evaluate escalating doses of SNDX-5613 monotherapy in phase 1. After the recommended dose is established, patients will be enrolled in 1 of 3 cohorts: acute lymphoblastic leukemia or mixed phenotype acute leukemia; KMT2A(MLL)-rearranged AML; and NPM1-mutant AML.8

Read more:
MLL Fusion Proteins Emerge as a Promising Target in AML - OncLive

Read More...

Wielding Powerful Imaging Tools, MSK Researchers Decipher Process of DNA Repair – On Cancer – Memorial Sloan Kettering

Friday, December 4th, 2020

Summary

Using cryo-electron microscopy, researchers at the Sloan Kettering Institute have gained an important insight into how cells repair broken DNA, a process fundamental to life that sometimes goes awry in cancer.

A landmark in cancer research was the discovery, in the early 1990s, of two cancer predisposition genes BRCA1 and BRCA2. When mutated, these genes increase a persons risk of developing several forms of cancer, including breast, ovarian, and prostate cancers. Since then, researchers around the world have been studying these genes and the proteins made from them to learn exactly how they increase the risk of cancer.

Many crucial breakthroughs in scientists understanding of this topic have come from research conducted at Memorial Sloan Kettering. In the late 1990s, Sloan Kettering Institute molecular biologist Maria Jasin showed that the BRCA2 protein was necessary for repairing a type of DNA damage called a double-strand break. When BRCA2 is mutated, it cant repair this damage well, and cancer is often the result.

In 2002, SKI structural biologist Nikola Pavletich determined the structure of the BRCA protein and showed that it binds to DNA. In a follow-up paper published in 2005, Dr. Pavletich showed that BRCA2 is required for DNA repair because it activates another protein, called Rad51, which is the actual machine that repairs double-strand breaks. In 2008, he showed how the bacterial version of Rad51, called RecA, starts the repair process by binding to one strand of the broken DNA.

Now, more than 12 years later, Dr. Pavletich has added yet another piece to the puzzle. In a report published October 14 in the journal Nature, he and his colleagues, including senior research scientist Haijuan Yang, describe the mechanism by which RecA and the broken DNA strand it carries search for the correct segment of a nearby DNA molecule to use as a repair template.

The findings cap a nearly 20-year quest, the pace of which has accelerated in recent years thanks to a new technology called cryo-electron microscopy (cryo-EM).

Because DNA is so fundamental to life, cells have evolved a variety of means to preserve its integrity. When DNA is damaged say by UV light or x-rays there are several ways a cell can attempt to repair it. The most careful, error-free way is called homologous recombination. In this type of repair, a cell finds a segment of DNA on an intact chromosome that matches the broken region of the other and uses that as a template to fill in the gap. (Chromosomes come in pairs, one from mom, one from dad; these chromosomes are said to be homologous.)

From decades of work, it was clear that a single strand of broken DNA finds homologous DNA with the help of a protein called RecA. RecA and single-stranded DNA form a structure called a pre-synaptic filament. The filament binds to double-strand DNA, opens it up to expose its complementary strands, and then searches for homology along one of those strands.

The question we didnt understand was how its searching for homology between the single-stranded DNA that its carrying and the double-stranded DNA that it binds to, Dr. Pavletich says.

To investigate that question, they turned to cryo-EM. This relatively new form of microscopy, whose developers won the 2017 Nobel Prize in Chemistry, allows scientists to visualize the fine-grained structure of biological molecules at unparalleled resolution. MSK acquired a cryo-EM machine in 2017.

Before the advent of cryo-EM, the main way that biologists determined structures of proteins and other molecules was x-ray crystallography, a painstaking and time-consuming effort.

Weve spent a long time with crystallography trying to address these issues and it just did not work out, Dr. Pavletich says. Cryo-EM makes it much easier.

Part of the problem is that to really understand the mechanism, they needed to capture what the RecA protein looks like at various points during the DNA repair process; with x-ray crystallography, they were really only able to look at one point in time.

With cryo-EM, they are able to look at thousands and thousands of RecA proteins bound to DNA at various times points and from these many images piece together the entire sequence.

What we were able to determine is how RecA opens the double-stranded DNA and how one of the DNA strands is sequestered at a second secondary site in the RecA protein, Dr. Pavletich says.

This binding leaves the other DNA strand flipping around and hitting the single-stranded DNA that the filament was carrying, he adds. If there is homology, it stays there. If there are no homology it continues to float around.

Even if the team had had several x-ray crystal structures to work with, they wouldnt have been able to glean what they were able to using a million RecA-DNA particles. Thats the power of cryo-EM, he says. It took us 12 years to solve this, but if we had had cryo-EM in 2008 then it would have been much faster.

Homologous recombination is not only important in fixing mutations that can lead to cancer. Its also how genetic diversity is generated during the formation of sperm and egg: maternal and paternal chromosomes break along their lengths and swap segments before being repaired through homologous recombination. This genetic diversity is why you and your siblings look similar but not identical; you each got a different combination of maternal and paternal chromosomes.

Homologous recombination is also how the genome-editing tool CRISPR works. This technology, whose developers won the 2020 Nobel Prize in Chemistry, relies on the introduction of DNA double-strand breaks at specific locations in the genome and repair through homologous recombination.

Dr. Pavletich says he hopes the new insights into homologous recombination will ultimately help improve cancer care, as past discoveries have done. But he says thats not the primary goal of basic science research.

As scientists, we do what we do because we love the gratification of solving a problem, he says. And homologous recombination is one of those really longstanding and important biological problems to understand. So it feels really good to be able to make this contribution to science.

Visit link:
Wielding Powerful Imaging Tools, MSK Researchers Decipher Process of DNA Repair - On Cancer - Memorial Sloan Kettering

Read More...

Is Sutro Biopharma Inc (STRO) the Top Pick in the Biotechnology Industry? – InvestorsObserver

Friday, December 4th, 2020

Sutro Biopharma Inc (STRO) is near the top in its industry group according to InvestorsObserver. STRO gets an overall rating of 65. That means it scores higher than 65 percent of stocks. Sutro Biopharma Inc gets a 81 rank in the Biotechnology industry. Biotechnology is number 35 out of 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 65 would rank higher than 65 percent of all stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Sutro Biopharma Inc (STRO) stock is trading at $16.67 as of 12:19 PM on Thursday, Dec 3, a gain of $0.32, or 1.96% from the previous closing price of $16.35. The stock has traded between $16.23 and $17.59 so far today. Volume today is 309,465 compared to average volume of 322,449.

Click Here to get the full Stock Score Report on Sutro Biopharma Inc (STRO) Stock.

View post:
Is Sutro Biopharma Inc (STRO) the Top Pick in the Biotechnology Industry? - InvestorsObserver

Read More...

Is Cellectar Biosciences Inc (CLRB) Stock Near the Top of the Biotechnology Industry? – InvestorsObserver

Friday, December 4th, 2020

A rating of 80 puts Cellectar Biosciences Inc (CLRB) near the top of the Biotechnology industry according to InvestorsObserver. Cellectar Biosciences Inc's score of 80 means it scores higher than 80% of stocks in the industry. Cellectar Biosciences Inc also received an overall rating of 65, putting it above 65% of all stocks. Biotechnology is ranked 35 out of the 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Cellectar Biosciences Inc (CLRB) stock is trading at $2.29 as of 2:18 PM on Thursday, Dec 3, an increase of $0.34, or 17.18% from the previous closing price of $1.95. The stock has traded between $1.95 and $2.40 so far today. Volume today is high. So far 8,826,004 shares have traded compared to average volume of 928,593 shares.

Click Here to get the full Stock Score Report on Cellectar Biosciences Inc (CLRB) Stock.

Read the original:
Is Cellectar Biosciences Inc (CLRB) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

Read More...

Reaping the promise of biotechnology – Business Mirror

Friday, December 4th, 2020

IT has been nearly two decades since the Philippine government approved the sale and cultivation of genetically modified (GM) corn seeds in local farms. The government issued a permit to commercialize Monsanto Philippiness bacillus thuringiensis (Bt) corn variety dubbed YieldGard on December 5, 2002. With this, the Philippines earned the distinction of being the first in Asia to commercialize Bt corn, a variety that enables corn farmers to save on production cost because they will no longer have to extensively use pesticides to kill the corn borera grain pest, particularly of corn.

Bt corn has been largely instrumental in increasing farmers production in the ensuing years following the issuance of the permit to Monsanto. The increment in output allowed the Philippines to become self-sufficient in corn (See, Yellow corn yield achieved 103 percent self-sufficiency last yearPiol, in the BusinessMirror, March 28, 2018). With the help of the biotech product, farmers were able to earn $642 million from 2003 to 2015, according to the International Service for the Acquisition of Agri-biotech Applications.

Its advantages and its potential to boost incomes have encouraged more farmers to plant the variety in recent years. The United States Department of Agricultures Foreign Agricultural Service in Manila noted that areas planted with Bt corn in the Philippines expanded by 26 percent to 834,617 hectares this year (See, Gain report: GE corn areas in PHL continue to expand, in the BusinessMirror, November 30, 2020). The availability of more yellow corna raw material used in manufacturing animal feedshas also supported the growing livestock and poultry industry.

These developments illustrate the benefits of biotechnology as well as its potential to enable the Philippines to develop other products that will allow farmers to diversify to other crops as well as cope with the ill effects of climate change. Currently, Bt corn is the only biotech product that is being planted in the Philippines. The GM varieties of other crops, like eggplant, are in various stages of development.

It is also worth noting that the Bt corn variety that was approved for commercialization in 2002 was made in the United States. The Philippines has yet to develop its own GM crop, and we urge Philippine researchers and scientists to make biotech products that are tailor fit to local conditions. Government must support these efforts by putting more money in the research initiatives of our local scientists or introduce policies, such as incentives, that will encourage the private sector to partner with them.

The recent successive typhoons that struck the Philippines should serve as a stark reminder of the increasing difficulties being faced by Filipino farmers and the pressing need for government to look for more sustainable means of ensuring food security. We welcome the Department of Agricultures (DA) pronouncement that it will optimize the use of biotechnology and other science-based solutions to increase farm output from limited farmlands and fishing grounds.

We urge Congress to support the DAs initiatives by passing the proposed Modern Biotechnology Act and by increasing the budget for agricultural research and development. Fully supported, our own scientists can harness the power of modern biotechnology.

Originally posted here:
Reaping the promise of biotechnology - Business Mirror

Read More...

The vaccines of tomorrow: how to invest in biotechnology – Rask Media

Friday, December 4th, 2020

Biotechnology has experienced extraordinary growth in recent times and came to popular attention as companies raced to find vaccines and cures for COVID-19. While investing in this area has obvious appeal from a social and moral perspective, it can also be a highly lucrative space as a growth investment in a portfolio.

Biotechnology specifically refers to technologies that use biological processes, capturing companies that focus on research, development, manufacturing and/or marketing of products based on biological and genetic information. The different types of biotechnology include biological drugs, vaccines, immunotherapy, gene therapy, orphan drugs and genetic engineering.

Biotechnology is predicted to be valued at more than US$833.34bn by 2027, compared to US$447.92 billion at the end of 2019, and will continue to grow, driven by the growing global population and the need for affordable, effective treatments and vaccines.Biotechnology will also be a beneficiary of population aging, particularly in Western countries. The reason for this is that an increase in the volume of older citizens is likely to have an accompanying and proportional increase in the volume of age-related diseases such as cardiovascular disease, dementia or arthritis, all requiring treatment.

Gilead is one example of a company with prospects in this space. Gilead is already well-known for its highly effective HIV treatments but is also targeting US and European approvals to market a drug called Filgotinib to treat rheumatoid arthritis.

In a demonstration of the growth in this industry, this year alone, 30-35 biotechnology companies are anticipated to go public, raising approximately US$3.5 billion.

The healthcare sector as a whole is likely to see greater investment as a result of the COVID-19 pandemic. For example, national health spending growth in the US is expected to average 5.4% annually through 2028, reaching US$6 trillion a year. Biotechnology will also be a beneficiary of this increased investment.

Investment and value from biotechnology is expected to grow in the coming years. While the trend already existed due to continuous tech improvements and the needs of a growing population, the COVID-19 pandemic has created a new spotlight on this area which may accelerate its growth.

Australian investors are likely to already be exposed to this growth segment in the concentrated domestic market. However, they may be missing exposure to the US, which dominates the global market for biotechnology.

Biotechnology could be considered part of a sector allocation to healthcare, or investors might view it as a thematic investment. You can find more information about thematic investing and using it in your portfolio in our latest whitepaper.

There are a range of ways to access the biotechnology industry.Investors could consider direct shares in biotechnology companies or alternatively consider managed funds. Direct shares can be a high-risk approach due to the high failure rates of drug testing and long periods of development (i.e., long periods where there may be no or a limited return on investment). Theres also the element of chance has the investor picked the winner? It could take years to know.

Managed investments, be it actively managed funds or passive options like ETFs, can assist in managing risk by spreading it across a larger number of companies. Investors could choose to invest by taking a sector approach and investing in a fund focusing on broader healthcare, or look at industry-specific options focusing on biotechnology. ETFS S&P Biotech ETF (ASX Code: CURE) is one such example that offers broad exposure to US biotechnology.

Read more:
The vaccines of tomorrow: how to invest in biotechnology - Rask Media

Read More...

Where Does Agenus Inc (AGEN) Stock Fall in the Biotechnology Field? – InvestorsObserver

Friday, December 4th, 2020

The 62 rating InvestorsObserver gives to Agenus Inc (AGEN) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 76 percent of stocks in the Biotechnology industry, AGENs 62 overall rating means the stock scores better than 62 percent of all stocks.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Agenus Inc (AGEN) stock is down -1.52% while the S&P 500 is higher by 0.15% as of 12:22 PM on Thursday, Dec 3. AGEN is down -$0.06 from the previous closing price of $3.63 on volume of 1,217,123 shares. Over the past year the S&P 500 has risen 18.04% while AGEN is down -9.14%. AGEN lost -$1.09 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Agenus Inc (AGEN) Stock.

Read the original here:
Where Does Agenus Inc (AGEN) Stock Fall in the Biotechnology Field? - InvestorsObserver

Read More...

Nanoparticles In Biotechnology And Pharmaceuticals Market Detail Analysis Focusing On Application, Types and Regional Outlook – Cheshire Media

Friday, December 4th, 2020

Nanoparticles In Biotechnology And Pharmaceuticals Market includes Overview, classification, industry value, price, cost and gross profit. It also covers types, enterprises and applications. To start with, analytical view to complete information of Nanoparticles In Biotechnology And Pharmaceuticals market. It offers market view by regions with countries, development in Nanoparticles In Biotechnology And Pharmaceuticals industry, opportunity with challenges, sales strategies, growth strategies and revenue analysis to include price.

The global Nanoparticles in Biotechnology and Pharmaceuticals market is valued at xx million US$ in 2018 and will reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Nanoparticles in Biotechnology and Pharmaceuticals market based on company, product type, end user and key regions.

Get Free Sample PDF for Professional Insights:https://www.researchmoz.us/enquiry.php?type=S&repid=2404724

Nanoparticles In Biotechnology And Pharmaceuticals Market report helps to analyses competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the Global Nanoparticles In Biotechnology And Pharmaceuticals Market Sales 2020 Industry Trend and Forecast 2026.

Market Segment by Type, covers

FullerenesLiquid CrystalsLiposomesNanoshellsQuantum dots

Nanoparticles In Biotechnology And Pharmaceuticals Market Segment by Applications, can be divided intoBiotechnologyPharmaceutical

Market Segment by Regions, regional analysis covers North America (United States, Canada and Mexico) Europe (Germany, UK, France, Italy, Russia, Spain and Benelux) Asia Pacific (China, Japan, India, Southeast Asia and Australia) Latin America (Brazil, Argentina and Colombia) Middle East and Africa

Enquiry for Discount or to Get Customized Report:https://www.researchmoz.us/enquiry.php?type=D&repid=2404724

Table of Contents: Nanoparticles In Biotechnology And Pharmaceuticals Market

Get Assistance on this report at:https://www.researchmoz.us/enquiry.php?type=E&repid=2404724

For More Information Kindly Contact:ResearchMozMr. Rohit Bhisey,90 State Street,Albany NY,United States 12207Tel: +1-518-621-2074USA-Canada Toll Free: 866-997-4948Email:[emailprotected]Follow us on LinkedIn @http://bit.ly/1TBmnVGMedia Release:https://www.researchmoz.us/pressreleaseFollow me on : https://nextgenmarketresearch.blogspot.com/

Continued here:
Nanoparticles In Biotechnology And Pharmaceuticals Market Detail Analysis Focusing On Application, Types and Regional Outlook - Cheshire Media

Read More...

Page 39«..1020..38394041..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick